Mylan NV's (MYL) shares fall 5% to $39.65 in after-hours trading Wednesday after the drugmaker says in a regulatory filing that U.S. health regulators have found "minor deficiencies" in its proposed generic version of GlaxoSmithKline PLC's asthma blockbuster Advair. The Food & Drug Administration is to send Mylan the rejection notice, called a complete response letter, on June 27. Mylan, which didn't offer any details on the deficiencies found, said it would then determine if it needs to adjust its 2018 forecast. (maria.armental@wsj.com; @mjarmental)

(END) Dow Jones Newswires

June 13, 2018 20:16 ET (00:16 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Mylan NV Charts.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Mylan NV Charts.